M&A / Deals Jeito Capital secures over $1.2bn for new biopharma investments Pharmaceutical Business ReviewThe milestone increases Jeito's assets under management to 1.6bn, following the 534m closure of Jeito I in 2021.M&A / DealsRead full story pharminent April 9, 2026 (Last updated: April 9, 2026) Pharmaceutical Business Review The milestone increases Jeito’s assets under management to 1.6bn, following the 534m closure of Jeito I in 2021. M&A / DealsRead full story Post navigation Previous: FDA seeks permanent future for rare pediatric priority review vouchersNext: EverSea Medicines to acquire Hasten Biopharmaceuticals Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026